Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ALKSBullishCorporate Developmentsnews

High materiality9/10

Alkermes Surges After Positive LUMRYZ Study Results and Analyst Upgrades

May 12, 2026, 2:51 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The positive REVITALYZ study results and analyst upgrades indicate a strong likelihood of continued investor interest, similar to past drug approval catalysts that spurred stock prices.

AI summary

What happened, with direct paths to the underlying reporting

Alkermes' LUMRYZ drug proved effective in the REVITALYZ study, prompting plans for a supplemental FDA application. The stock recent surge and analyst upgrades suggest continued positive sentiment and potential growth ahead, making it a focus for investors.

The REVITALYZ study showed LUMRYZ's significant efficacy in treating narcolepsy.
Alkermes plans to file a supplemental NDA with the FDA by late 2026.
LUMRYZ currently approved for narcolepsy but not idiopathic hypersomnia.
Alkermes shares recently surged and reached a new 52-week high.
Analysts have raised price targets for ALKS stock, reflecting optimism.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.